IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.033
EU - Europa 7.401
AS - Asia 5.052
Continente sconosciuto - Info sul continente non disponibili 27
SA - Sud America 26
AF - Africa 24
OC - Oceania 17
Totale 22.580
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.933
CN - Cina 4.971
IE - Irlanda 2.215
UA - Ucraina 1.539
FI - Finlandia 1.084
DE - Germania 808
SE - Svezia 709
IT - Italia 497
GB - Regno Unito 323
FR - Francia 117
CA - Canada 87
IN - India 37
RU - Federazione Russa 37
BE - Belgio 31
IR - Iran 22
EU - Europa 20
MU - Mauritius 17
AU - Australia 16
NL - Olanda 13
PA - Panama 9
BO - Bolivia 8
BR - Brasile 7
TR - Turchia 7
CL - Cile 6
RO - Romania 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AT - Austria 4
CO - Colombia 4
LV - Lettonia 4
ZA - Sudafrica 4
CH - Svizzera 3
ES - Italia 3
JP - Giappone 3
MX - Messico 3
PL - Polonia 3
BD - Bangladesh 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
EG - Egitto 2
HK - Hong Kong 2
XK - ???statistics.table.value.countryCode.XK??? 2
CR - Costa Rica 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
QA - Qatar 1
TW - Taiwan 1
Totale 22.580
Salva come PNG Salva come JPEG
Città #
Chandler 2.220
Dublin 2.212
Jacksonville 1.998
Nanjing 1.553
Ashburn 699
Nanchang 613
Princeton 517
Lawrence 496
Wilmington 489
Hebei 462
Shenyang 452
Changsha 392
Jiaxing 371
Medford 350
Beijing 274
Hangzhou 240
Helsinki 227
Tianjin 227
Boardman 214
Ann Arbor 206
New York 134
Milan 129
Woodbridge 110
Norwalk 96
Verona 76
Toronto 71
Pavia 69
Seattle 61
Shanghai 57
Falls Church 54
Jinan 51
Fairfield 42
Los Angeles 39
Washington 38
Des Moines 37
Kunming 34
Ningbo 33
Zhengzhou 33
Brussels 31
Houston 30
Taizhou 28
Tappahannock 21
Guangzhou 20
Auburn Hills 17
Dearborn 13
Lanzhou 13
Borås 12
Pune 12
Redwood City 12
San Francisco 12
Fuzhou 11
Rome 11
Florence 9
La Paz 8
Leawood 8
Panama City 8
Changchun 7
Naples 7
Falkenstein 6
Haikou 6
Kemerovo 6
Melbourne 6
Orange 6
Goiânia 5
Monmouth Junction 5
Novokuznetsk 5
Trento 5
Ardabil 4
Brignano Gera D'adda 4
Gallarate 4
Manchester 4
Montespertoli 4
Napoli 4
Ottawa 4
Zanjan 4
Andover 3
Bovisio Masciago 3
Canberra 3
Catania 3
Delhi 3
Isfahan 3
Munich 3
Redmond 3
Rochester 3
Saint Paul 3
San Luis Obispo 3
Taranto 3
Alghero 2
Antony 2
Bari 2
Berlin 2
Binetto 2
Boston 2
Cairo 2
Cape Town 2
Casatenovo 2
Chicago 2
Dello 2
Fano 2
Ferrara 2
Totale 15.810
Salva come PNG Salva come JPEG
Nome #
Anemia associata ad endocrinopatie. 91
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 88
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 88
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 86
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 84
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 82
Further concerns about the medical risks of blood doping. 79
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 79
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 76
A case of persistent eosinophilia 76
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 75
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 75
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 75
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 75
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 74
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 74
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 73
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 73
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 73
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 70
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 70
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 70
Blast phase of essential thrombocythemia: A single center study. 69
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 69
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 69
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 69
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 68
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 68
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 67
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 67
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 67
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 67
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 66
Classification and prognostic evaluation of myelodysplastic syndromes 66
A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. 66
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 65
Deferoxamine in thalassemia major. 65
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy: cytokinetic effects on bone marrow hematopoietic progenitors. 65
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 65
Leukemia risk models in primary myelofibrosis: an International Working Group study. 65
Policitemia vera. 65
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 65
JAK inhibitor in CALR-mutant myelofibrosis 65
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 64
JAK2 (V617F) mutation in healthy individuals 64
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 64
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production 64
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 64
Effects of desferrrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies 63
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders 63
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 63
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells. 63
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 63
A translational link between Fe and Epo 63
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 63
Classification of anaemia on the basis of ferrokinetic parameters. 63
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 63
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 63
Translational pathophysiology: a novel molecular mechanism of human disease 62
Erythrokinetics and mechanisms of anaemia in hereditary elliptocytosis and hereditary ovalocytosis. 62
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 62
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 62
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms 62
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 62
Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza") 61
Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. 61
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 61
Mitochondrial ferritin: a new player in iron metabolism 61
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 60
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 60
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 60
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 60
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 60
X-linked Wiskott-Aldrich syndrome in a girl. 60
Policitemia vera. 60
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 60
Genetic disorders of iron overload and the novel ''ferroportin disease'' 59
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 59
Pincered red cells and hereditary spherocytosis. 59
Expression of adhesion molecules and functional stimulation in human neutrophils: modulation by GM-CSF and role of the Bcr gene. 59
Clinical significance of somatic mutation in unexplained blood cytopenia 59
Myelodysplastic syndromes: recent advances 58
Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes 58
Studio morfologico e citochimico dei megacariociti in 25 casi di displasie emopoietiche. 58
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 58
Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. 58
An improved method for liquid scintillation counting of 59Fe in ferrokinetic studies. 58
Diabetes insipidus in the preleukaemic phase of acute non-lymphocytic leukaemia. A monosomy 7-associated condition? 58
A chronic lymphoproliferative disorder 58
A rare lymphoma with skin involvement 58
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms 58
Clinical and biological implications of driver mutations in myelodysplastic syndromes 58
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 58
Revised international prognostic scoring system for myelodysplastic syndromes 58
Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis 57
Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time 57
Natural history of juvenile haemochromatosis 57
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 57
Hematologic passport for athletes competing in endurance sports: a feasibility study. 57
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 57
Totale 6.541
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.902
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201972 0 0 0 0 0 0 0 0 0 0 9 63
2019/20206.086 1.832 2.556 10 285 8 316 74 356 30 468 145 6
2020/20212.860 335 257 76 300 7 378 31 453 126 439 374 84
2021/20222.194 32 8 67 39 101 130 40 119 120 93 341 1.104
2022/20236.374 745 374 48 520 634 706 3 404 2.642 33 165 100
2023/20242.120 254 448 96 207 220 623 65 137 15 53 2 0
Totale 23.115